Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

AstraZeneca’s Imfinzi and tremelimumab show promise in non-small cell lung cancer study

The company is exploring novel combinations of monoclonal antibodies.

By Brian Buntz | September 10, 2021

AstraZenecaAstraZeneca (LON: AZN) announced that Imfinzi (durvalumab) together with tremelimumab and platinum-based chemotherapy improved overall survival by 23% and progression-free survival by 28% compared to chemotherapy alone in patients with Stage IV (metastatic) non-small cell lung cancer (NSCLC). The data came from a Phase 3 trial known as POSEIDON.

Imfinzi and tremelimumab are immune checkpoint inhibitors.

“The POSEIDON data offer patients further benefit from Imfinzi and are an important validation of our development strategy to explore novel combinations,” said Susan Galbraith, AstraZeneca’s executive vice president, oncology R&D.

Imfinzi is a human monoclonal antibody that targets programmed death-ligand 1 (PD-L1).

While many Big Pharma firms have developed PD-L1 drugs, few have become blockbusters — Bristol Myers Squibb’s Yervoy (ipilimumab) is one exception.

The POSEIDON trial had 338 recipients who received Imfinzi, tremelimumab and chemotherapy. Another 337 received chemotherapy alone.

A 2020 study published in Medicine found that durvalumab and tremelimumab combination therapy was well tolerated and demonstrated clinical benefit in treating head and neck squamous cell carcinoma. That study concluded that more evidence was needed to confirm the benefit of using the two drugs together.

FDA first approved Imfinzi for advanced bladder cancer on May 1, 2017. It is now approved for unresectable Stage III non-small cell lung cancer and extensive-stage small cell lung cancer. Earlier this year, the company voluntarily withdrew the indication for advanced bladder cancer.

The safety profile of the combination of durvalumab, tremelimumab and chemotherapy was similar to that of chemotherapy alone.


Filed Under: clinical trials, Drug Discovery, Oncology
Tagged With: AstraZeneca, chemotherapy, durvalumab, Imfinzi, non-small cell lung cancer, POSEIDON, tremelimumab
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Diversity
Making diversity in clinical research more than a talking point
psychedelic medicine discussed at SXSW
5 headwinds and 5 tailwinds for psychedelic medicine
lab microscope
Accelerating R&D with FAIR data
Kallyope
Kallyope’s focus on the gut-brain axis yields a diverse portfolio

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50